Silvano Spinelli

In 2018, Silvano became Venture Partner at Sofinnova.

Silvano is the founder and chairman of the board of BiovelocITA, the first Italian biotechnology accelerator, sponsored by Sofinnova. He founded EOS SpA (Ethical Oncology Science), a portfolio company of Sofinnova Capital V, in 2006 and was its CEO until the acquisition of the company by Clovis Oncology, Inc in 2013 for a maximum amount of 470 M $.

Silvano was the co-founder and CEO of Novuspharma, a holding company of Sofinnova Capital III. In 2000, the company went public on the Italian market Nuovo Mercato, raising more than 160 million euros. Novuspharma was acquired by Cell Therapeutics, Inc. (CTI) in 2003.

Silvano was responsible for R & D at Boehringer Mannheim Italy. He holds a degree in organic chemistry from the University of Pisa. Sofinnova has been the main investor in all of these initiatives.